Tau-targeted treatment strategies in Alzheimer's disease
about
Connecting the dots between tau dysfunction and neurodegenerationProteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson diseaseFisetin stimulates autophagic degradation of phosphorylated tau via the activation of TFEB and Nrf2 transcription factorsMolecular investigations of protriptyline as a multi-target directed ligand in Alzheimer's diseaseSecondary Metabolites in Ramalina terebrata Detected by UHPLC/ESI/MS/MS and Identification of Parietin as Tau Protein InhibitorShort-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease miceSmall molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice.Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.Human neural stem cells alleviate Alzheimer-like pathology in a mouse model.Roles of tau protein in health and disease.Mechanisms of Alzheimer's Disease Pathogenesis and Prevention: The Brain, Neural Pathology, N-methyl-D-aspartate Receptors, Tau Protein and Other Risk Factors.A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory.Fragile X mental retardation protein: from autism to neurodegenerative disease.Tau reduction prevents disease in a mouse model of Dravet syndromeENU mutagenesis screen to establish motor phenotypes in wild-type mice and modifiers of a pre-existing motor phenotype in tau mutant mice.Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.Alzheimer's disease models and functional genomics-How many needles are there in the haystack?Soluble forms of tau are toxic in Alzheimer's disease.Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders.Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies.Absence of Tau triggers age-dependent sciatic nerve morphofunctional deficits and motor impairmentRole of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approachesLessons from two prevalent amyloidoses-what amylin and Aβ have in commonA clinical approach to early-onset inheritable dementia.The impact of mass spectrometry on the study of intact antibodies: from post-translational modifications to structural analysis.Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Alzheimer disease therapy--moving from amyloid-β to tau.Invited review: Drug development for tauopathies.Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer's Disease: What are the Roadblocks and How Can They Be Overcome?First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model.β-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer's disease.Tau exacerbates excitotoxic brain damage in an animal model of stroke.Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease.Souvenaid®: a new approach to management of early Alzheimer's disease.The Molecular Chaperone Artemin Efficiently Blocks Fibrillization of TAU Protein In Vitro.Energetics of Excitatory and Inhibitory Neurotransmission in Aluminum Chloride Model of Alzheimer's Disease: Reversal of Behavioral and Metabolic Deficits by Rasa Sindoor.Low Erythrocyte Levels of Proteasome and Acyl-Peptide Hydrolase (APEH) Activities in Alzheimer's Disease: A Sign of Defective Proteostasis?[(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease.Tau-targeting passive immunization modulates aspects of pathology in tau transgenic mice.Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.
P2860
Q26996848-CDAB5769-2D04-4CAA-B933-92D808DF0C95Q27005843-F7793944-BA17-477F-9D7D-2D13F2DF6B25Q28393031-D1A661BC-C0F5-4511-BA1D-750F69028CBCQ28542431-76B9DE5F-A140-4C9D-BC59-947F8BAE9768Q28828799-8588EDF8-871F-4778-886C-3ABA89EDF238Q30541295-44D2FDD0-09E6-4C5D-8DE8-01DE3AA89DEFQ30611779-DC4E51EA-D9F3-4580-A752-7573B96873DFQ30651551-65682E10-EBCC-4FD8-A57A-8CBD712248B6Q30662068-B1B0CC6C-0FE9-4BD7-8365-A21031195F92Q33559303-F951E698-FF2B-4C93-9A2D-D103C51BF78FQ34550307-7C7C5E07-6E9E-41FE-B63F-BF5DAE6E9365Q35040016-DA896BAC-4AF7-4D04-B48A-46B5143D73D9Q35077291-955203C1-9731-4B29-ABA5-1C1BEAC7D45AQ35115219-92609F21-8A87-4F85-BC47-492085CE7CAAQ35636403-90894F55-8ED9-414B-971F-44CD601C627DQ36189198-A2132A31-FDFE-4949-A547-0D9C27062C63Q36193841-2C19AFB7-AED3-4673-8834-E2786B219C70Q36286360-9093C59C-7160-48A0-A627-941185509520Q36484413-947A4226-B592-4550-BBEF-4B741274BCB8Q36558485-5444FB27-FA66-48B2-8EF5-7D50828E7C84Q36665475-CF8F0AD2-06DA-4E1A-B278-E6A130C3115BQ36830938-2789A806-E937-4DD6-A5E2-7F6CC51CA0A4Q37080680-2CEC958B-80BB-4D1C-9E63-8A57F0BD087DQ38008963-2E9668E1-4DF1-440C-881E-676577DA698BQ38062785-C89DD3B3-C211-4721-9C4F-1C1510090DA7Q38079317-44AB95C6-32EC-4F41-8244-DC928FD2D38BQ38161786-53EBB24C-7841-46A5-85C4-6E263598F421Q38263698-3754F24D-61FD-454A-82FC-F00009767CAEQ38592069-9020DC84-E8A7-4CC9-B7A5-ED169297DB52Q39083050-934CEF1A-0FAF-447F-8234-2AAAAD4C4737Q39234405-313128C5-F2CE-4732-A343-E3889EE5D768Q41545476-44BBF1FA-C32D-48E8-9652-60659E3EEF00Q42026368-F986995C-BD44-40C5-8B3D-64963975A1C4Q43864462-4FF2055C-04DA-4C9D-8C12-6C3C082A6663Q47137171-5BF48F40-BA96-4F71-9E6A-1489D1F28B40Q47167624-574F110E-DBDB-4B85-87B1-FE5C3AA5B12EQ47687700-47F837FD-BB9E-404B-82C2-962D007CC832Q48271057-5629007E-3BE3-471A-B657-B00B93D78235Q48650483-7D6F08E6-ADAE-41D3-A815-5A6BA770C685Q50632272-68F85CF8-1B23-463A-805A-23223E6C87F4
P2860
Tau-targeted treatment strategies in Alzheimer's disease
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Tau-targeted treatment strategies in Alzheimer's disease
@ast
Tau-targeted treatment strategies in Alzheimer's disease
@en
Tau-targeted treatment strategies in Alzheimer's disease
@nl
type
label
Tau-targeted treatment strategies in Alzheimer's disease
@ast
Tau-targeted treatment strategies in Alzheimer's disease
@en
Tau-targeted treatment strategies in Alzheimer's disease
@nl
prefLabel
Tau-targeted treatment strategies in Alzheimer's disease
@ast
Tau-targeted treatment strategies in Alzheimer's disease
@en
Tau-targeted treatment strategies in Alzheimer's disease
@nl
P2860
P50
P3181
P1476
Tau-targeted treatment strategies in Alzheimer's disease
@en
P2860
P304
P3181
P356
10.1111/J.1476-5381.2011.01713.X
P407
P577
2012-03-01T00:00:00Z